Organovo Holdings (NASDAQ:ONVO) Stock

Organovo Holdings

Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.

GE_Healthcare_Amersham_radiopharmaceuticals_packaging

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

ASLN

CERO

ONVO

Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July

xr:d:DAFrIeSK2eI:2,j:4239412416966744852,t:23081009

Movers

AIXI

ARGX

BYND

CDLX

COMP

CPOP

CTMX

DUOL

EXAS

MGNI

NUKK

SEZL

TIVC

Why AppLovin Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket

Penny Stocks

Small Cap

Intraday Update

ADIL

AEYE

Alterity Therapeutics Limited - American Depositary Shares

ATHE

BHVN

BTCY

CENX

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

DXYZ

EGIO

EXTR

HUBC

IMCC

INFA

KAVL

KUKE

LGVN

LOCL

MNDR

MRNS

NMRA

Nuveen California Dividend Advantage Municipal Fund 2

NXPL

PROK

PSNY

QTTB

RARE

RENT

SNGX

SNPO

SPCB

SPWR

SRFM

SWVL

TCON

VERU

VIAO

WIRE

Shares of  Ultragenyx Pharmaceutical Inc.  (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Organovo Holdings Inc

Management

Organovo Appoints Norman Staskey As CFO

On December 23, 2024, Hess, the Company's former President, Chief Financial Officer and Principal Financial Officer, notified the Company of his intent to resign and resigned effective December 24, 2024, from his part-time role to pursue retirement.&nbsp;
Hess's resignation is not a result of any disagreement with the Company or any matter relating to its accounting or financial policies or procedures.
 &nbsp;

Organovo Holdings Appoints Norman Staskey As President, CFO And Principal Financial Officer, Effective December 30, 2024, In Connection With Resignation Of Tomas Hess - Filing

Biotech

General

Organovo Highlights Phase 2 Results For FXR314 In MASH At The Liver Meeting, Showing Significant Liver Fat Reduction And Improved Safety Profile Compared To Other FXR Agonists

WIIM

Organovo Holdings shares are trading higher after the company announced it will present clinical data of FXR314 in its Phase 2 MASH study in an oral presentation sponsored by the American Association for the Study of Liver Diseases.

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces that its lead clinical stage drug, FXR314 will be featured in an oral presentation at The Liver Meeting, sponsored by the American Association for the Study of Liver Diseases (AASLD). The presentation, by Dr. Eric Lawitz of the Texas Liver Institute, will describe the findings from the FXR314 Phase 2 MASH study. The meeting will be held November 15-19, 2024 in San Diego, California.

Organovo To Present Clinical Data Of FXR314 In Phase 2 MASH In An Oral Presentation At The Liver Meeting Sponsored By The American Association For The Study Of Liver Diseases

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. `
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Aslan Pharmaceuticals Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLN#NASDAQ">ASLN</a>)</h3>
<ul>
<li>On July 17, ASLAN Pharmaceuticals announced that its Singapore-incorporated, sole operating subsidiary has filed for voluntary liquidation. The company said this decision was made following a thorough review of ASLAN SG's financial situation and strategic options. The company's stock fell around 69% over the past five days and has a <a href="https://www.benzinga.com/quote/ASLN">52-week low of $0.48</a>.</li>
<li>RSI Value: 25.34</li>
<li>ASLN Price Action: Shares of Aslan Pharmaceuticals fell 37% to close at $0.70 on Wednesday.</li>
<li><a href="https://pro.benzinga.com/dashboard">Benzinga Pro's real-time newsfeed</a> alerted to latest Aslan Pharmaceuticals news.</li>
</ul>
<h3 class="wp-block-heading">CERo Therapeutics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>)&nbsp;&nbsp;&nbsp;&nbsp;</h3>
<ul>
<li>On June 13, the company executed pre-IND manufacturing activities for its lead therapeutic, CER-1236. The company's stock fell around 33% over the past month. It <a href="https://www.benzinga.com/quote/CERO">has a 52-week low</a> of $0.16.</li>
<li>RSI Value: 20.79</li>
<li>CERO Price Action: Shares of CERo Therapeutics gained 6.2% to close at $0.21 on Wednesday.</li>
<li>Benzinga Pro's charting tool helped identify the <a href="https://pro.benzinga.com/dashboard">trend in CERO stock</a>.</li>
</ul>
<h3 class="wp-block-heading">Organovo Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>)</h3>
<ul>
<li>On July 16, Organovo presented the company&#8217;s outlook and plans at Jones Trading Healthcare Conference. The company's stock dipped around 18% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/ONVO">low of $0.55</a>.</li>
<li>RSI Value: 20.53</li>
<li>ONVO Price Action: Shares of Organovo fell 5.2% to close at $0.59 on Wednesday.</li>
<li>Benzinga Pro's signals feature notified of a potential <a href="https://pro.benzinga.com/dashboard">breakout in Organovo shares</a>.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39814553/jim-cramer-says-dont-sell-match-group-youve-just-got-a-very-very-smart-investor-in-there">Jim Cramer Says Don&#8217;t Sell Match Group: &#8216;You&#8217;ve Just Got A Very, Very Smart Investor In There</a>&#8216;</li>
</ul>

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037603" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037603">https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/12037603</a>

Organovo Granted U.S. Patent #12037603: Methods for tissue fabrication

Organovo Presents Company's Outlook And Plans At Jones Trading Healthcare Conference; Encourages Review Of FXR314 Presentation Amid Strong M&A Activity In IBD; Highlights Progress And Upcoming Phase 2a Trial Of FXR314 For IBD

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) including ulcerative colitis, today announces data from a poster presented at Digestive Disease Week (DDW2024) demonstrating the potential of the Company's lead clinical-stage compound, FXR314, in combination with tofacitinib for treating inflammatory bowel disease (IBD) using 3D models and preclinical models. DDW2024 is being held in Washington, D.C. May 18-21, 2024.

Organovo Reports Data Demonstrating Potential For FXR314 As Combination Therapy With Tofacitinib For Inflammatory Bowel Disease Presented At Digestive Disease Week

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11982668" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11982668">https://ppubs.uspto.gov/dirsearch-public/print/downloadPdf/11982668</a>

Tech

Organovo Granted U.S. Patent #11982668:	Use Of Engineered Renal Tissues In Assays

Organovo Holdings shares are trading lower after the company announced the pricing of a $5.25 million public offering of 6,562,500 shares and common warrants.

Shares of AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) rose sharply in today's pre-market trading after the company reported better-than-expected <a href="https://www.benzinga.com/news/earnings/24/05/38715910/applovin-stock-jumps-on-strong-q1-earnings-the-details">first-quarter financial results</a>.
The company posted revenue of $1.058 billion, versus estimates of $974.361 million. Its earnings came in at 67 cents per share, versus expectations of 55 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
AppLovin shares jumped 14.8% to $85.00 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Pop Culture Group Co., Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPOP#NASDAQ">CPOP</a>) gained 60.3% to $2.71 in pre-market trading. Pop Culture reported revenue of $24 million for the six months ended Dec. 31, 2023, up from $12.75 million in the year-ago period.</li>
<li>Sezzle Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEZL#NASDAQ">SEZL</a>) gained 36.1% to $60.87 in pre-market trading after reporting first-quarter results.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVP#NASDAQ">IVP</a>) shares rose 21.6% to $4.41 in pre-market trading. Inspire Veterinary Partners recently announced a 1-for-100 reverse stock split.</li>
<li>Nukkleus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) rose 17.7% to $1.04 in today's pre-market trading.</li>
<li>Xiao-I Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIXI#NASDAQ">AIXI</a>) shares gained 14.3% to $1.44 in pre-market trading after the company reported a strategic partnership with a leading Hong Kong Insurance Company to enhance AI-driven customer service.</li>
<li>TuanChe Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TC#NASDAQ">TC</a>) jumped 13% to $2.61 in pre-market trading.</li>
<li>Treasure Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGL#NASDAQ">TGL</a>) gained 12.6% to $5.35 in pre-market trading. Treasure Global is expected to report its financial results for the third quarter of fiscal year 2024, after the closing bell on Tuesday, May 14.</li>
<li>Compass, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COMP#NYSE">COMP</a>) shares rose 12.5% to $3.69 in pre-market trading after posting first-quarter results.</li>
<li>Magnite, Inc.(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) shares gained 10.6% to $9.85 in pre-market trading after the company reported first-quarter financial results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) fell 36.7% to $0.8487 in pre-market trading. Tivic Health Systems shares jumped around 28% on Wednesday after the company announced the final results of its pilot research study on cervical vagus nerve stimulation.</li>
<li>CytomX Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) shares declined 35.6% to $2.70 in pre-market trading after the company reported first-quarter financial results and announced initial data from the ongoing CX-904 Phase 1a dose escalation clinical study, demonstrating a favorable safety profile and confirmed anti-cancer activity.</li>
<li>Cardlytics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDLX#NASDAQ">CDLX</a>) shares fell 28.8% to $10.40 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) fell 27.2% to $0.6969 in pre-market trading after the company priced its $5.25 million public offering of 6,562,500 common shares and common warrants at a combined price of $0.80.</li>
<li>Delta Apparel, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLA#NYSE">DLA</a>) fell 23.5% to $2.15 pre-market trading following weaker-than-expected second-quarter results.</li>
<li>Bioventus Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BVS#NASDAQ">BVS</a>) shares fell 20% to $4.03 in pre-market trading. Bioventus recently reported better-than-expected first-quarter financial results and raised its FY24 guidance above estimates.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares declined 17.4% to $49.15 in pre-market trading after the company reported mixed first-quarter financial results.</li>
<li>Beyond Meat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) shares fell 13.4% to $7.11 in pre-market trading after the company reported a wider-than-expected loss for its first quarter. The company sees second-quarter revenue to be between $85 million and $90 million and full-year 2024 revenue to be between $315 million and $345 million.</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) shares declined 12.4% to $213.95 in pre-market trading after the company reported first quarter financial results.</li>
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) fell 7.4% to $357.60 pre-market trading after the company reported first quarter financial results and issued a business update.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/05/38722280/roblox-beyond-meat-and-3-stocks-to-watch-heading-into-thursday">Roblox, Beyond Meat And 3 Stocks To Watch Heading Into Thursday</a>

Reported Earlier, Organovo Prices $5.25M Public Offering Of 6,562,500 Common Shares And Common Warrants At A Combined Price Of $0.80

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches based on demonstration of clinical promise in three-dimensional (3D) human tissues, today announced the pricing of a public offering consisting of 6,562,500 shares of common stock (or pre-funded warrants in lieu thereof) and common warrants to purchase up to an aggregate of 6,562,500 shares of its common stock, at a combined public offering price per share of common stock and accompanying common warrant to purchase one share of common stock of $0.80 (or $0.799 per share subject to pre-funded warrants and accompanying warrant to purchase one share of common stock). &nbsp;
The common warrants will have an exercise price of&nbsp;$0.80&nbsp;per share, will be immediately exercisable upon issuance and have a term of five years after their original issuance date. The gross proceeds from the offering, before deducting placement agent fees and other offering expenses payable by the Company, are expected to be&nbsp;$5.25 million&nbsp;(excluding any proceeds that may be received upon the exercise of the common warrants). The offering is expected to close on or about&nbsp;May 13, 2024, subject to the satisfaction of customary closing conditions.
JonesTrading Institutional Services LLC ("Jones") is acting as the exclusive placement agent for the offering.

Offerings

Organovo Holdings, Inc. Announces Pricing Of $5.25M Public Offering Of  6,562,500 Shares Of Common Stock  And Common Warrants At A Combined Price Of $0.80

<h3>Gainers</h3>
<ul>
<li>Dynatronics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYNT#NASDAQ">DYNT</a>) stock rose 84.9% to $0.69 during Tuesday's pre-market session. The company's market cap stands at $3.3 million. </li>
<li>BioRestorative Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRTX#NASDAQ">BRTX</a>) shares rose 23.48% to $1.63. The market value of their outstanding shares is at $11.0 million. </li>
<li>Akanda (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAN#NASDAQ">AKAN</a>) shares increased by 23.0% to $0.14. The company's market cap stands at $1.6 million. </li>
<li>Cullinan Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGEM#NASDAQ">CGEM</a>) shares moved upwards by 20.89% to $20.01. The company's market cap stands at $861.6 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) stock moved upwards by 18.85% to $76.97. The market value of their outstanding shares is at $7.4 billion. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares moved upwards by 15.07% to $0.85. The market value of their outstanding shares is at $5.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) shares fell 24.3% to $8.32 during Tuesday's pre-market session. The company's market cap stands at $194.4 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock decreased by 22.5% to $0.47. The market value of their outstanding shares is at $16.5 million. </li>
<li>Dermata Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRMA#NASDAQ">DRMA</a>) stock decreased by 20.06% to $0.24. The market value of their outstanding shares is at $1.5 million. </li>
<li>Addex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADXN#NASDAQ">ADXN</a>) shares declined by 12.69% to $21.61. The company's market cap stands at $22.8 million. </li>
<li>Poseida Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSTX#NASDAQ">PSTX</a>) shares fell 12.66% to $2.12. The market value of their outstanding shares is at $204.7 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares decreased by 10.38% to $1.21. The company's market cap stands at $12.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADXN

AKAN

ALZN

BRTX

CGEM

CLDI

DRMA

DYNT

ITCI

PSTX

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rare#NASDAQ">RARE</a>) fell sharply during Monday&rsquo;s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.</li>
<li>Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) surged 54% to $2.6350 following insider buys from multiple company executives.</li>
<li>SuperCom Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spcb#NASDAQ">SPCB</a>) shares gained 39.4% to $0.3849 after jumping around 18% on Friday.</li>
<li>Piedmont Lithium Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pll#NYSE">PLL</a>) shares gained 32.1% to $16.75 following a 5% decline on Friday.</li>
<li>Snap One Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/snpo#NASDAQ">SNPO</a>) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies.</li>
<li>Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.</li>
<li>Kuke Music Holding Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kuke#NASDAQ">KUKE</a>) jumped 27% to $2.7650.</li>
<li>HUB Cyber Security Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hubc#NASDAQ">HUBC</a>) gained 24% to $1.61 after gaining over 11% on Friday.</li>
<li>Edgio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egio#NASDAQ">EGIO</a>) gained 24% to $22.18.</li>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kavl#NASDAQ">KAVL</a>) surged 23.6% to $3.30.</li>
<li>Envoy Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coch#NASDAQ">COCH</a>) gained 22.6% to $6.19.</li>
<li>Medical Properties Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) rose 19.9% to $4.7850 after the company announced that it sold its majority interest in Utah Hospitals.</li>
<li>CareMax, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cmax#NASDAQ">CMAX</a>) climbed 19.5% to $3.78.</li>
<li>SES AI Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ses#NYSE">SES</a>) surged 18.7% to $1.77.</li>
<li>Mobile-health Network Solutions (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mndr#NASDAQ">MNDR</a>) gained 17.7% to $17.67.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) rose 16.7% to $2.72.</li>
<li>ProKidney Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prok#NASDAQ">PROK</a>) gained 16.7% to $2.0426.</li>
<li>Biotricity, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/btcy#NASDAQ">BTCY</a>) rose 16.5% to $1.34.</li>
<li>Yatsen Holding Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ysg#NYSE">YSG</a>) gained 13.3% to $3.41.</li>
<li>Destiny Tech100 Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NASDAQ">DXYZ</a>) shares gained 12.8% to $32.71 after dipping 42% on Friday.</li>
<li>Encore Wire Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wire#NASDAQ">WIRE</a>) surged 11.7% to $291.60 after the company entered an agreement to be acquired by Prysmian for $290 per share in cash.</li>
<li>Century Aluminum Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cenx#NASDAQ">CENX</a>) gained 9.5% to $18.05.</li>
<li>Extreme Networks, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/extr#NASDAQ">EXTR</a>) gained 5.7% to $11.31. B. Riley Securities analyst Dave Kang upgraded Extreme Networks from Neutral to Buy and maintained a $14 price target.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dipped 77% to $1.6800 after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.</li>
<li>Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) fell 35% to $8.58.</li>
<li>VIA optronics AG (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/viao#NASDAQ">VIAO</a>) dipped 34% to $0.2765.</li>
<li>Veru Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/veru#NASDAQ">VERU</a>) fell 24% to $1.1550. Oppenheimer analyst Leland Gershell reiterated Veru with an Outperform and lowered the price target from $7 to $5.</li>
<li>Rent the Runway, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rent#NASDAQ">RENT</a>) dipped 19.8% to $15.42.</li>
<li>NextPlat Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxpl#NASDAQ">NXPL</a>) fell 19.8% to $1.50 after jumping 24% on Friday. The company entered into a definitive business combination agreement with its majority-owned subsidiary Progressive Care Inc.</li>
<li>Cyngn Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cyn#NASDAQ">CYN</a>) shares fell 19.1% to $0.1170 after declining around 7% on Friday.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) fell 15.6% to $1.95.</li>
<li>Biohaven Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bhvn#NASDAQ">BHVN</a>) dipped 15.4% to $44.90. Biohaven showcased innovative neuroscience portfolio with 20 presentations at the 2024 AAN Annual Meeting.</li>
<li>Neumora Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nmra#NASDAQ">NMRA</a>) shares declined 15.1% to $11.48 after the FDA placed a clinical hold on the company&#39;s Phase 1 NMRA-266 study.</li>
<li>Alterity Therapeutics Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/athe#NASDAQ">ATHE</a>) dipped 15% to $2.49.</li>
<li>Surf Air Mobility Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srfm#NASDAQ">SRFM</a>) fell 15% to $0.53.</li>
<li>IM Cannabis Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imcc#NASDAQ">IMCC</a>) fell 14.2% to $0.5399.</li>
<li>Polestar Automotive Holding Uk Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/psny#NASDAQ">PSNY</a>) fell 12.7% to $1.2699. On Friday, Cantor Fitzgerald analyst Andres Sheppard reiterated Polestar Automotive with an Overweight and maintained a $5 price target.</li>
<li>Desktop Metal, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dm#NYSE">DM</a>) fell 10.8% to $0.8510.</li>
<li>Local Bounti Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/locl#NYSE">LOCL</a>) declined 10.2% to $2.1550.</li>
<li>Q32 Bio Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qttb#NASDAQ">QTTB</a>) fell 10% to $26.00.</li>
<li>SunPower Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/spwr#NASDAQ">SPWR</a>) fell 8.3% to $2.2750.</li>
<li>Informatica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/infa#NASDAQ">INFA</a>) dipped 8.1% to $35.36 amid increased volatility following reports suggesting Salesforce is in talks to buy the company.</li>
<li>TRACON Pharmaceuticals Inc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) declined 8.1% to $2.1699 after falling around 9% on Friday.</li>
<li>NOVONIX Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nvx#NYSE">NVX</a>) declined 7.2% to $2.63.</li>
<li>AudioEye, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeye#NASDAQ">AEYE</a>) fell 6.6% to $12.86 after declining around 7% on Friday.</li>
<li>OncoCyte Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocx#NASDAQ">OCX</a>) fell 6.6% to $2.5301. Oncocyte announced a transplant assay partnership agreement with Bio-Rad laboratories.</li>
<li>BlackBerry Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bb#NYSE">BB</a>) fell 6.1% to $2.8650.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38249138/dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings"> Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings</a>

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) stock moved upwards by 44.4% to $2.44 during Monday's regular session. The market value of their outstanding shares is at $7.7 million. </li>
<li>Mobile-health Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNDR#NASDAQ">MNDR</a>) shares rose 35.53% to $20.33. The company's market cap stands at $691.2 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares moved upwards by 31.89% to $0.12. The company's market cap stands at $32.8 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock increased by 30.35% to $0.5. The market value of their outstanding shares is at $5.2 million. </li>
<li>ProKidney (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROK#NASDAQ">PROK</a>) stock increased by 26.33% to $2.21. The company's market cap stands at $136.2 million. </li>
<li>Organovo Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares moved upwards by 24.58% to $1.26. The market value of their outstanding shares is at $12.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) shares fell 79.8% to $1.52 during Monday's regular session. The market value of their outstanding shares is at $83.4 million. </li>
<li>Alterity Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATHE#NASDAQ">ATHE</a>) stock decreased by 20.07% to $2.35. The company's market cap stands at $20.5 million. </li>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock decreased by 18.76% to $1.1. The market value of their outstanding shares is at $10.3 million. </li>
<li>Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) shares fell 18.16% to $1.8. The market value of their outstanding shares is at $74.6 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) stock fell 17.42% to $0.94. The market value of their outstanding shares is at $13.9 million. As per the news, the Q4 earnings report came out today. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock declined by 17.15% to $1.16. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BSGM

JAGX

LIFW

RLYB

SXTC

12 Health Care Stocks Moving In Monday's Intraday Session

Organovo Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONVO#NASDAQ">ONVO</a>) shares are trading higher Monday after the company announced <a href="https://www.benzinga.com/news/earnings/24/04/38249138/dow-jumps-over-300-points-goldman-sachs-posts-upbeat-earnings">Phase 2 results for FXR314.&nbsp;</a>
The Details:
Organovo<a href="https://www.benzinga.com/pressreleases/24/04/g38246154/organovo-announces-positive-phase-2-results-for-fxr314-in-metabolic-dysfunction-associated-steatoh"> released </a>the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314 for the treatment of metabolic function-associated steatohepatitis (MASH).&nbsp;
Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo, and FXR314 was also found to be safe and well tolerated.
&#8220;The key findings of this study are that once daily oral FXR314 demonstrated statistically significant liver fat reduction and excellent tolerability. Whereas other FXR agonists have had challenges in providing clear benefit without significant pruritus or other adverse events, or have had lack of efficacy potentially related to lack of sustained exposure, we are pleased to note FXR314&#8217;s data demonstrate it clearly rises above previous problems seen with the class,&#8221; stated Keith Murphy, Organovo&#8217;s Executive Chairman. 
Organovo shares are moving on heavy trading volume following the release of Phase 2 results Monday. According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, more than 45 million shares have already been traded in the session, compared to the stock&#8217;s 100-day average of less than 102,000 shares.
Related News: <a href="https://www.benzinga.com/news/24/04/38227765/whats-going-on-with-palantir-stock">What&#8217;s Going On With Palantir Stock?</a>
Is ONVO A Good Stock To Buy?
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/ONVO">Organovo Holdings</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. Organovo Holdings does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 16.59%, you'll need to buy a share of Orchid Island Cap by the April 29. Once done, you can expect to receive a nominal payout of $0.12 on May. 30.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/ONVO">Organovo Holdings</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
ONVO Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Organovo Holdings shares are up 29.7% at $1.31 at the time of publication Monday.
Image from Shutterstock

Why Organovo Stock Is Up Today

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday.
The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&amp;P 500 also rose, gaining, 0.80% to 5,164.30.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38218786/best-buy-box-and-2-other-stocks-insiders-are-selling"> Best Buy, Box And 2 Other Stocks Insiders Are Selling </a>
&nbsp;
<h3>Leading and Lagging Sectors</h3>
&nbsp;
Financial shares jumped by 1.5% on Friday.
In trading on Friday, real estate shares rose by just 0.3%.
&nbsp;
<h3>Top Headline</h3>
&nbsp;
Goldman Sachs Group Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gs#NYSE">GS</a>) reported better-than-expected first-quarter earnings on Monday.
Goldman Sachs reported revenue of $14.21 billion for the first quarter of 2024, beating the consensus of $12.92 billion. The U.S. financial services giant reported EPS of $11.58, beating the consensus of $8.60.
&nbsp;
<h3>Equities Trading UP</h3>
&nbsp;
Soligenix, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sngx#NASDAQ">SNGX</a>) shares shot up 98% to $0.7699 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Shares of Longeveron Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvn#NASDAQ">LGVN</a>) got a boost, surging 70% to $2.87 following insider buys from multiple company executives.
Organovo Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onvo#NASDAQ">ONVO</a>) shares were also up, gaining 23% to $1.2613 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.
&nbsp;
<h3>Equities Trading DOWN</h3>
&nbsp;
Marinus Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrns#NASDAQ">MRNS</a>) shares dropped 76% to $1.7680 after the company provided an update on the Phase 3 RAISE trial and reported preliminary Q1 financial results.
Shares of ProMIS Neurosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pmn#NASDAQ">PMN</a>) were down 29% to $1.63.
PaxMedica, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pxmd#NASDAQ">PXMD</a>) was down, falling 23% to $0.6501. PaxMedica, last week, announced the completed execution of three pivotal registration/validation batches of PAX-101.
Also Check This Out:<a href="https://www.benzinga.com/news/24/04/38246593/wall-streets-most-accurate-analysts-views-on-3-tech-stocks-with-over-4-dividend-yields"> Wall Street&#39;s Most Accurate Analysts&#39; Views On 3 Tech Stocks With Over 4% Dividend Yields </a>
&nbsp;
<h3>Commodities</h3>
&nbsp;
In commodity news, oil traded up 0.5% to $85.43 while gold traded down 0.8% at $2,353.50.
Silver traded down 0.6% to $28.075 on Friday, while copper rose 0.1% to $4.2580.
&nbsp;
<h3>Euro zone</h3>
&nbsp;
European shares were higher today. The eurozone&rsquo;s STOXX 600 rose 0.8%, London&rsquo;s FTSE 100 gained 0.1% while Spain&rsquo;s IBEX 35 Index rose 0.6% The German DAX gained 1.4% French CAC 40 climbed 1.3% while Italy&rsquo;s FTSE MIB Index jumped 1.5%.
Industrial production in the eurozone increased by 0.8% month-over-month in February.
&nbsp;
<h3>Asia Pacific Markets</h3>
&nbsp;
Asian markets closed mostly lower on Monday, with Japan&rsquo;s Nikkei 225 falling 0.74%, Hong Kong&rsquo;s Hang Seng Index dropping 0.72%, China&rsquo;s Shanghai Composite gaining 1.26% and India&rsquo;s S&amp;P BSE Sensex dipping 1.14%.
Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.
&nbsp;
<h3>Economics</h3>
&nbsp;
The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month&rsquo;s reading of -20.9.
Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38248683/bitcoin-surpasses-66-000-core-emerges-as-top-gainer"> Bitcoin Surpasses $66,000; Core Emerges As Top Gainer </a>

Earnings

Eurozone

Commodities

Global

PXMD

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings

Organovo shares are trading higher after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.

Press Releases

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo

Financing

Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)

Health Care

Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease

Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases

Organovo Presents Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting

Comments

Organovo Holdings

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga